Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 6:12:669373.
doi: 10.3389/fgene.2021.669373. eCollection 2021.

Editorial: Genetics of Familial Hypercholesterolemia: New Insight

Alpo Vuorio  1   2 , Uma Ramaswami  3   4 , Kirsten B Holven  5   6
Affiliations
Editorial

Editorial: Genetics of Familial Hypercholesterolemia: New Insight

Alpo Vuorio et al. Front Genet. .
No abstract available

Keywords: LDL cholesterol; PCSK9 inhibitors; atherosclerosis; familial hypercholesterolemia; mutations; statins.

PubMed Disclaimer

Conflict of interest statement

KH has received research grants or honoraria from Mills AS, Tine SA, Olympic Seafood, Amgen, Sanofi, none of which are related to the content of this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Genetics of Familial Hypercholesterolemia: New Insight

References

    1. Bogsrud M. P., Øyri L., Halvorsen S, Atar D., Leren T. P., Holven K. B. (2020). Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction. J. Clin. Lipidol. 14, 339–345. 10.1016/j.jacl.2020.04.002 - DOI - PubMed
    1. Futema M., Ramaswami U., Tichy L., Bogsrud M. P., Holven K. B., Roeters van Lennep J., et al. . (2021). Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 319, 108–117. 10.1016/j.atherosclerosis.2021.01.008 - DOI - PubMed
    1. Hovingh G. K., Lepor N. E., Kallend D., Stoekenbroek R. M., Wijngaard P. L. J., Raal F. J. (2020). Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 Pilot study. Circulation 141, 1829–1831. 10.1161/CIRCULATIONAHA.119.044431 - DOI - PubMed
    1. Humphries S. E., Cooper J., Dale P., Ramaswami U., F. H Paediatric Register Steering Group (2018). The UK Paediatric familial hypercholesterolaemia register: statin-related safety and 1-year growth data. J. Clin. Lipidol. 12, 25–32. 10.1016/j.jacl.2017.11.005 - DOI - PMC - PubMed
    1. Iqbal Z., Ho J. H., Adam S., France M., Syed A., Neely D. (2020). Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis 313, 126–136. 10.1016/j.atherosclerosis.2020.09.008 - DOI - PMC - PubMed

Publication types

LinkOut - more resources